去纤维钠治疗肝小静脉闭塞病疗效怎么样？

Also called defibrotide, it is suitable for the treatment of adults and children with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT).

Defibrinated sodium injection is administered based on patient weight, with the recommended dose being 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. Administer defibrinated sodium for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrination until resolution of VOD or up to a maximum of 60 days. Note: Defibrinated sodium must be diluted before infusion. Do not coadminister with other intravenous medications at the same time and in the same intravenous line.

How effective is defibrinated sodium in the treatment of hepatic veno-occlusive disease?

The effectiveness of defibrinated sodium was evaluated through three research trials on 528 patients. The subjects participating in the three trials were all patients diagnosed with VOD symptoms after HSCT and accompanied by abnormal liver or renal function. The overall survival rate 100 days after HSCT was used as the evaluation index. The results showed that the survival rate after 100 days of defibrotide sodium treatment was 38% to 45%; while data analysis found that the survival rate of HSCT patients who were expected to receive only supportive care or other drug intervention after 100 days was only 21% to 31%.

Defibrotide sodium (defibrotide) is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide sodium can act on these receptors to produce a variety of downstream effects. In recent years, multiple clinical research results have shown that defibrotide sodium (defibrotide) is a safe and effective drug for preventing and treating hepatic veno-occlusive disease.

The above is an introduction to the effect of treating hepatic veno-occlusive disease. If you need to purchase this medicine, you can also consult your medical companion for purchase information.